Bardenheier, B. H., Duderstadt, S. K., Engler, R. J. & McNeil, M. M. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009–2010 season in the active component US military and civilians aged 17–44 years reported to the Vaccine Adverse Event Reporting System. Vaccine 34, 4406–4414 (2016).
Halsey, N. A. et al. Algorithm to assess causality after individual adverse events following immunizations. Vaccine 30, 5791–5798 (2012).
Halsey, N. A. et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine 31, 6107–6112 (2013).
Johann-Liang, R., Josephs, S. & Dreskin, S. C. Analysis of anaphylaxis cases after vaccination: 10-year review from the National Vaccine Injury Compensation Program. Ann. Allergy Asthma Immunol. 106, 440–443 (2011).
Zheng, W. & Dreskin, S. C. Thimerosal in influenza vaccine: an immediate hypersensitivity reaction. Ann. Allergy Asthma Immunol. 99, 574–575 (2007).
Vaccine Adverse Event Reporting System (CDC, accessed 31 December 2021); https://vaers.hhs.gov/
Banerji, A. et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J. Allergy Clin. Immunol. Pract. 9, 1423–1437 (2021).
Summary of the Meetings of the Monitoring Committee on the Vaccination Campaign (Israel Ministry of Health, accessed 8 August 2021); https://govextra.gov.il/ministry-of-health/covid19-vaccine/covid-19-vaccine-efficacy-safety-follow-up-committee/
McMahon, D. E. et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J. Am. Acad. Dermatol. 85, 46–55 (2021).
Castells, M. C. & Phillips, E. J. Maintaining safety with SARS-CoV-2 vaccines. N. Engl. J. Med. 384, 643–649 (2021).
Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412–1423 (2021).
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
Coronavirus (COVID-19) Vaccinations (Our World in Data, accessed 29 January 2022); https://ourworldindata.org/covid-vaccinations
Liotti, L. et al. COVID-19 vaccines in children with cow’s milk and food allergies. Nutrients 13, 2637 (2021).
Seneff, S. & Nigh, G. Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. Int. J. Vaccine Theory Pract. Res. 2, 402–443 (2021).
Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States (CDC, accessed 10 February 2021); https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
Szebeni, J., Simberg, D., González-Fernández, Á., Barenholz, Y. & Dobrovolskaia, M. A. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat. Nanotechnol. 13, 1100–1108 (2018).
Gold, M. S. et al. Immunization stress-related response—redefining immunization anxiety-related reaction as an adverse event following immunization. Vaccine 38, 3015–3020 (2020).
Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Review Memorandum (USFDA, 2020); https://www.fda.gov/media/144416/download
FDA Briefing Document Moderna COVID-19 Vaccine (USFDA, 2020); https://www.fda.gov/media/144434/download
Ellis R. Pfizer: vaccine shown 100% effective in kids 12–15 WebMD (31 March 2021); https://www.webmd.com/vaccines/covid-19-vaccine/news/20210331/pfizer-vaccine-effectiveness-kids-twelve-to-fifteen
Yanez Arteta, M. et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl Acad. Sci. USA 115, E3351–E3360 (2018).
Mui, B. L. et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol. Ther. Nucleic Acids 2, E139 (2013).
Viger-Gravel, J. et al. Structure of lipid nanoparticles containing siRNA or mRNA by dynamic nuclear polarization-enhanced NMR spectroscopy. J. Phys. Chem. B 122, 2073–2081 (2018).
Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release 217, 345–351 (2015). Establishes the proof of principles for the LNP-mRNA delivery in vivo.
Liang, F. et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther 25, 2635–2647 (2017).
Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).
Lindsay, K. E. et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat. Biomed. Eng. 3, 371–380 (2019). Provides insights into the fate of mRNA vaccine after the immunization.
Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509–1519 (2018).
Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594–599 (2020). Provides the proof of efficacy of Pfizer/Biontech vaccine in humans.
Anderson, E. J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 383, 2427–2438 (2020). Reports the results of clinical trials accessing toxicity and efficacy of COVID-19 632 vaccine in humans.
Karikó, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).
Lokugamage, M. P. et al. Mild innate immune activation overrides efficient nanoparticle-mediated RNA delivery. Adv. Mater. 32, e1904905 (2020).
Pollard, C. et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21, 251–259 (2013).
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
Coombs R. R. A. & Gell P. G. H. in Clinical Aspects of Immunology 2nd edn (eds Gell P. G. H. & Coombs R. R. A.) 575–596 (Blackwell Scientific, 1968).
Simons, F. E. et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 12, 389–399 (2012).
Szebeni, J. Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals. Mol. Immunol. 61, 163–173 (2014). Provides a comprehensive literature review of complement-mediated infusion reactions to nanomedicines.
del Balzo, U., Polley, M. J. & Levi, R. Cardiac anaphylaxis. Complement activation as an amplification system. Circ. Res. 65, 847–857 (1989).
Castells, M. Diagnosis and management of anaphylaxis in precision medicine. J. Allergy Clin. Immunol. 140, 321–333 (2017).
Sloane, D. et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J. Allergy Clin. Immunol. Pract. 4, 497–504 (2016).
Common Terminology Criteria for Adverse Events (CTCAE) (US Department of Health and Social Services, 2017); https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Jacubovic, B. D., Sanchez-Sanchez, S., Hamadi, S., Lynch, D. & Castells, M. Interleukin-6: A novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association. Allergy 76, 1571–1573 (2021).
Blumenthal, K. G. et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N. Engl. J. Med. 384, 1273–1277 (2021).
Garvey, L. H. & Nasser, S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br. J. Anaesth. 126, e106–e108 (2021).
Moghimi, S. M. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines. Mol. Ther. 29, 898–900 (2021).
Chen, B. M. et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal Chem 88, 10661–10666 (2016).
Neun, B. W., Barenholz, Y., Szebini, J. & Dobrovolskaia, J. M. Understanding the role of anti-PEG antibodies in the complement activation by doxil in vitro. Molecules 23, 1700 (2018).
Horváth, A. et al. Anti-cholesterol antibodies (ACHA) in patients with different atherosclerotic vascular diseases and healthy individuals. Characterization of human ACHA. Atherosclerosis 156, 185–192 (2001).
Alving, C. R. Natural antibodies against phospholipids and liposomes in humans. Biochem. Soc. Trans. 12, 342–344 (1984).
Kozma, G. T., Shimizu, T., Ishida, T. & Szebeni, J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv. Drug Deliv. Rev. 154-155, 163–175 (2020).
Suzuki, T. et al. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production. Int J Pharm 588, 119792 (2020).
Kozma, G. T. et al. Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions. ACS Nano 13, 9315–9324 (2019). Demonstrates the role of PEG-specific antibodies in complement activation related pseudoallergy. Reveals a similarity of hemodynamic changes in pigs to that of infusion reactions-related changes in humans
Jiang, H., Cooper, B., Robey, F. A. & Gewurz, H. DNA binds and activates complement via residues 14–26 of the human C1q A chain. J. Biol. Chem. 267, 25597–25601 (1992).
Pham, C. T. et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J. Biol. Chem. 286, 123–130 (2011).
Sedic, M. et al. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Vet. Pathol. 55, 341–354 (2018).
Chonn, A., Cullis, P. R. & Devine, D. V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146, 4234–4241 (1991).
Plank, C., Mechtler, K., Szoka, F. C. Jr. & Wagner, E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum. Gene Ther. 7, 1437–1446 (1996).
Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J. & Saifer, M. G. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug. Chem. 23, 485–499 (2012).
Comirnaty: Tozinameran/COVID-19 mRNA Vaccine (Nucleoside Modified) (European Medicines Agency, accessed 15 April 2021); https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty
mPEG-N,N-Ditetradecylacetamide (ALC-0159) (BiochemPEG, 2021); https://www.biochempeg.com/product/mPEG-N,N-Ditetradecylacetamide.html
Johnson, J. B., Aguilar, H. C., Lee, B. & Parks, G. D. Interactions of human complement with virus particles containing the Nipah virus glycoproteins. J. Virol. 85, 5940–5948 (2011).
Yu, J. et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 136, 2080–2089 (2020).
Kenawy, H. I., Boral, I., Bevington, A. & Complement-Coagulation Cross-talk: a potential mediator of the physiological activation of complement by low pH. Front. Immunol. 6, 215 (2015).
Ali, Y. M. et al. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front. Immunol. 12, 714511 (2021).
Ogata, A. F. et al. Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin. Infect. Dis. 2021, ciab465 (2021).
Crooke, S. T. et al. Integrated safety assessment of 2′-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol. Ther. 24, 1771–1782 (2016).
Schirinzi, A. et al. Pentraxin 3: potential prognostic role in SARS-CoV-2 patients admitted to the emergency department. J. Infect. 82, 84–123 (2021).
Kolev, M., Le Friec, G. & Kemper, C. Complement—tapping into new sites and effector systems. Nat Rev Immunol 14, 811–820 (2014).
Li, C. et al. Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model. Clin. Infect. Dis. 2021, ciab707 (2021).
Krantz, M. S. et al. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don’t give up on the second dose! Allergy 76, 2916–2920 (2021).
Krantz, M. S. et al. Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose. JAMA Intern. Med. 181, 1530–1533 (2021).
Szebeni, J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216, 106–121 (2005).
Ilinskaya, A. N. et al. Nanoparticle physicochemical properties determine the activation of intracellular complement. Nanomedicine 17, 266–275 (2019).
Oliver, S. E. et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine—United States, December 2020. Morb. Mortal. Wkly Rep. 69, 1653–1656 (2021).
Stone, C. A. Jr. et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J. Allergy Clin. Immunol. Pract. 7, 1533–1540.e8 (2019).
Zhou, Z. H. et al. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J. Allergy Clin. Immunol. Pract. 9, 1731–1733.e3 (2021).
Selvaraj, G., Kaliamurthi, S., Peslherbe, G. H. & Wei, D. Q. Are the allergic reactions of COVID-19 vaccines caused by mRNA constructs or nanocarriers? Immunological insights. Interdiscip. Sci. 13, 344–347 (2021).
Kelso, J. M. IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines. Clin. Exp. Allergy 52, 10–11 (2021).
Sellaturay, P., Nasser, S., Islam, S., Gurugama, P. & Ewan, P. W. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin. Exp. Allergy 51, 861–863 (2021).
Kaakati, R., Khokhar, D. & Akin, C. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. J. Allergy Clin. Immunol. Pract. 9, 3198–3199 (2021).
Rama, T. A., Moreira, A. & Castells, M. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. J. Allergy Clin. Immunol. 147, 877–878 (2021).
Lyons, J. J. et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat. Genet. 48, 1564–1569 (2016).
Passia, E. & Jandus, P. Using baseline and peak serum tryptase levels to diagnose anaphylaxis: a review. Clin. Rev. Allergy Immunol. 58, 366–376 (2020).
Pflipsen, M. C. & Vega Colon, K. M. Anaphylaxis: recognition and management. Am. Fam. Physician 102, 355–362 (2020).
Warren, C. M. et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw. Open 4, e2125524 (2021).
Ali, H. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol. Lett. 128, 36–45 (2010).
Li, Y. et al. Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi. Nat. Med. 22, 952–960 (2016).
Li, Y. et al. A functional genomics approach to understand variation in cytokine production in humans. Cell 167, 1099–1110.e1014 (2016).
Dobrovolskaia, M. A. Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: challenges, considerations and strategy. J. Control Release 220, 571–583 (2015).
Van Hoecke, L. et al. The opposing effect of type I IFN on the T cell response by non-modified mRNA-lipoplex vaccines is determined by the route of administration. Mol. Ther. Nucleic Acids 22, 373–381 (2020).
Lei, H. et al. Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2. Signal Transduct. Target. Ther. 5, 291 (2020).
Ivanov, K., Garanina, E., Rizvanov, A. & Khaiboullina, S. Inflammasomes as targets for adjuvants. Pathogens 9, 252 (2020).
Reinke, S., Thakur, A., Gartlan, C., Bezbradica, J. S. & Milicic, A. Inflammasome-mediated immunogenicity of clinical and experimental vaccine adjuvants. Vaccines 8, 554 (2020).
Hosoki, K., Itazawa, T., Boldogh, I. & Sur, S. Neutrophil recruitment by allergens contribute to allergic sensitization and allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 16, 45–50 (2016).
Wittling, M. C., Cahalan, S. R., Levenson, E. A. & Rabin, R. L. Shared and unique features of human interferon-beta and interferon-alpha subtypes. Front. Immunol. 11, 605673 (2020).
Mezouar, S. & Mege, J. L. Changing the paradigm of IFN-γ at the interface between innate and adaptive immunity: macrophage-derived IFN-γ. J. Leukoc. Biol. 108, 419–426 (2020).
Cheng, M. H. et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc. Natl Acad. Sci. USA 117, 25254–25262 (2020).
Royall, J. A. et al. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am. J. Physiol. 257, L399–L410 (1989).
Burke-Gaffney, A. & Keenan, A. K. Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 alpha/beta, tumor necrosis factor-alpha and interferon-gamma. Immunopharmacology 25, 1–9 (1993).
Dobrovolskaia, M. A. et al. Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol. Pharm. 9, 382–393 (2012).
Novakowski, S., Jiang, K., Prakash, G. & Kastrup, C. Delivery of mRNA to platelets using lipid nanoparticles. Sci. Rep. 9, 552 (2019).
Zhang, S. et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J. Hematol. Oncol. 13, 120 (2020).
Jimenez-Rodriguez, T. W., Garcia-Neuer, M., Alenazy, L. A. & Castells, M. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. J. Asthma Allergy 11, 121–142 (2018).
Elzagallaai, A. A. et al. Role of oxidative stress in hypersensitivity reactions to sulfonamides. J. Clin. Pharmacol. 60, 409–421 (2020).
Mocan, T. et al. Implications of oxidative stress mechanisms in toxicity of nanoparticles (review). Acta Physiol. Hung. 97, 247–255 (2010).
Ilinskaya, A. N., Clogston, J. D., McNeil, S. E. & Dobrovolskaia, M. A. Induction of oxidative stress by Taxol vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA. Nanomedicine 11, 1925–1938 (2015).
Dobrovolskaia, M. A. & McNeil, S. E. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J. Control Release 172, 456–466 (2013).
Tezel, G. et al. Oxidative stress and the regulation of complement activation in human glaucoma. Invest. Ophthalmol. Vis. Sci. 51, 5071–5082 (2010).
Fevang, B. et al. Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin. Exp. Immunol. 142, 576–584 (2005).
Krebs, K. et al. Genome-wide study identifies association between HLA-B(∗)55:01 and self-reported penicillin allergy. Am. J. Hum Genet. 107, 612–621 (2020).
Nakatani, K. et al. Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens–Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing. Sci. Rep. 9, 16240 (2019).
Profaizer, T., Pole, A., Monds, C., Delgado, J. C. & Lázár-Molnár, E. Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. Hum. Immunol. 81, 354–360 (2020).
Shirayanagi, T. et al. Detection of abacavir-induced structural alterations in human leukocyte antigen-B*57:01 using phage display. Biol. Pharm. Bull. 43, 1007–1015 (2020).
Tangamornsuksan, W. et al. HLA genotypes and cold medicine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis with severe ocular complications: a systematic review and meta-analysis. Sci. Rep. 10, 10589 (2020).
Profaizer, T. & Eckels, D. HLA alleles and drug hypersensitivity reactions. Int. J. Immunogenet. 39, 99–105 (2012).
Fernandez, C. A. et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 124, 1266–1276 (2014).
Nguyen, A. et al. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. J. Virol. 94, 13 (2020).
23andMe Releases Data on HLA-genetics of COVID-19 Vaccine Response (Inside Precision Medicine, 2021); https://www.clinicalomics.com/topics/patient-care/therapeutics/vaccines/23andme-releases-data-on-hla-genetics-of-covid-19-vaccine-response/?utm_medium=newsletter&utm_source=Clinical+OMICs+Update&utm_content=01&utm_campaign=Clinical+OMICs+Update_20211109&oly_enc_id=0917D2598689C8T
NIH Begins Study of Allergic Reactions to Moderna, Pfizer-BioNTech COVID-19 Vaccines (NIH News Releases, 2021); https://www.niaid.nih.gov/news-events/nih-begins-study-allergic-reactions-moderna-pfizer-biontech-covid-19-vaccines
Guidance for Health Care Providers: Understanding Severe Allergic Reactions to COVID-19 Vaccines (Toronto Public Health, 2021).
Lyons-Weiler, J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J. Transl. Autoimmun. 3, 100051 (2020).
Vojdani, A., Vojdani, E. & Kharrazian, D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front. Immunol. 11, 617089 (2020).
Thi, T. T. H. et al. The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation. Polymers 12, 252 (2020).
Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).
Ndeupen, S. et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. Iscience 24, 103479 (2021). Demonstrated in a mouse model that LNPs used for the delivery of mRNA vaccines cause a strong inflammatory response that contributes to the vaccine efficacy but is also responsible for the side effects.
Dézsi, L. et al. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor. GeroScience 1–22 (2022). Demonstrates in a pig model that injection of Comirnaty (Pfizer/BioNTech) vaccine causes hemodynamic changes in animals that are similar to the changes characteristic of infusion reactions to nanomedicines.
Pfizer-BioNTech COVID-19 Vaccine—Fact Sheet for Healthcare Providers Administering Vaccine (FDA, accessed 15 April 2021); https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine#additional
Corbett K. S., et al. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2020.06.11.145920v1 (2020).
Vardi N. Moderna’s mysterious coronavirus vaccine delivery system. Forbes https://www.forbes.com/sites/nathanvardi/2020/07/29/modernas-mysterious-coronavirus-vaccine-delivery-system/?sh=3d2bcb8462d9 (2020).
Felgner, P. et al. Nomenclature for synthetic gene delivery systems. Human Gene Therapy 8, 511–512 (1997).
O’Shaughnessy J.A. Letter of Authorization to Pfizer (FDA, accessed 30 January 2022); https://www.fda.gov/media/150386/download
Adverse Events Reporting System (USFDA, accessed 15 March 2021); https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard